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Traumatic Brain Injury (TBI) is one of the foremost causes of mortality secondary to trauma. Poorer outcomes are associated with secondary insults, after the initial
brain injury occurred. The management goal of TBI is to prevent or minimise the effects of secondary brain injuries. The primary objective of this systematic review/
meta-analysis was to assess the effects of Hypertonic Saline (HTS) compared to Standard Fluid Therapy (SFT) in the treatment and resuscitation of TBI patients. We
searched CENTRAL, MEDLINE (from 1966), EBSCOhost, Scopus, ScienceDirect, Proquest Medical Library and EMBASE (from 1980) in May 2010 and updated
searches in February 2011. Data were assessed and extracted by two independent authors. Risk ratios (RR) with a 95% conﬁdence interval (CI) were used as the effect
measure. The review included three RCTs (1184 participants) of which two were of high to moderate quality (1005 participants). HTS was not found to be associated
with a reduction in mortality (3 RCTs, 1184 participants, RR 0.91, 95%CI 0.76 to 1.09) and morbidity in TBI patients. No signiﬁcant improvement in haemodynamical
stability was found whereas insufﬁcient data were available to indicate a reduction in the intracranial pressure (ICP). In the HTS group, cerebral perfusion pressure
(CPP) (MD 3.83 mmHg, 95%CI 1.08 to 6.57) and serum sodium level (MD 8 mEq/L, 95%CI 7.47 to 8.53) were higher. Existing studies show no indication that HTS,
in comparison to SFT, reduces mortality or morbidity after the occurrence of TBI. Against this backdrop, some uncertainties still exist in terms of the use of different
concentrations and volumes of HTS, the timing of administration as well as the beneﬁt in speciﬁc injury proﬁles. As a result, formulating conclusive recommendations is
complex.Les traumatismes craˆniens (TC) constituent l’une des causes les plus importantes de mortalite´ conse´cutive a` un traumatisme. Les e´checs the´rapeutiques sont associe´s a`
des le´sions secondaires, suite a` la premie`re le´sion ce´re´brale. Le but de la HS en termes de gestion est de pre´venir ou de minimiser les effets des le´sions ce´re´brales sec-
ondaires. Le principal objectif de cette revue syste´matique/me´ta-analyse e´tait d’e´valuer les effets de la solution saline hypertonique (HS) par rapport a` la the´rapie de
re´hydratation standard (TRS) dans le traitement et la re´animation des patients souffrant de traumatismes ce´re´braux. Nous avons effectue´ des recherches dans les bases
de donne´es CENTRAL, MEDLINE (a` partir de 1966), EBSCOhost, Scopus, ScienceDirect, Proquest Medical Library et EMBASE (a` partir de 1980) en mai 2010 et
avons mis nos recherches a` jour en fe´vrier 2011. Les donne´es ont e´te´ e´value´es et extraites par deux auteurs inde´pendants. Des rapports de risque (RR) avec un intervalle
de conﬁance (IC) a` 95% ont e´te´ utilise´s comme mesure de l’effet. La revue incluait trois ECR (1 184 participants), dont deux e´taient de qualite´ bonne a` moyenne (1 005
participants). La revue n’a pas permis de re´ve´ler que la HS e´tait associe´e a` une re´duction de la mortalite´ (trois ECR, 1 184 participants, RR 0,91 a` un IC a` 95% compris
entre 0,76 et 1,09) et de la morbidite´ chez les patients victimes de traumatismes ce´re´braux. Aucune ame´lioration signiﬁcative de la stabilite´ he´modynamique n’a e´te´
note´e, et les donne´es permettant d’indiquer une re´duction de la pression intracraˆnienne (PIC) e´taient insufﬁsantes. Dans le groupe HS, la pression de perfusion ce´re´brale
(PPC) (DM 3,83 mmHg, IC a` 95% compris entre 1,08 et 6,57) et les taux de sodium se´rique (DM 8 mEq/L, IC a` 95% compris entre 7,47 et 8,53) e´taient plus e´leve´s. Les
e´tudes existantes n’indiquaient aucunement que la HS, par comparaison a` la TRS, permettait de re´duire la mortalite´ ou la morbidite´ suite a` un traumatisme ce´re´bral.
Dans un tel contexte, des incertitudes subsistent quant a` l’utilisation de diffe´rentes concentrations et volumes de HS, au moment de l’administration, ainsi qu’aux
be´ne´ﬁces possibles dans des proﬁls de le´sions spe´ciﬁques. Par conse´quent, la formulation de recommandations conclusives s’ave`re complexe.African relevance
 Traumatic Brain Injuries is a public health burden.
 High global and Africa rate of Traumatic Brain Injuries. High rate of inter-personal violent, motor vehicle accidents
as well as alcohol and drug abuse leading to high rates of
TBI in the Southern Africa and African regions.
 Burden of Traumatic Brain Injuries on family units.
Introduction
Traumatic Brain Injury (TBI) is the leading cause of injury-
related deaths and disability in children and young adults,
worldwide.1 Nearly 50% of all deaths related to injury are
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resulting in substantial burdens to individuals, families and
communities.1,5 Bryan-Hancock and Harrison 2010 estimate
the global TBI incidence at 200 per 100,000 people annually.
South Africa has an incidence of 1.5 to 3.5 times the global
rate.6 The United States has an annual TBI related death rate
of approximately 53,000.3 Motor vehicle accidents, falls and
interpersonal violence are the most common causes.1,3,7
Various studies have indicated that TBI is associated with
poorer outcomes when aggravated by secondary brain
injury,8 therefore treating TBI requires a multifaceted
approach. The initial injury, primary brain injury, occurs
as a result of external mechanical forces causing damage
to the scalp, cranium and intracranial contents. Secondary
brain injury is deﬁned as an additional insult to the brain
that occurs hours to days after the initial injury and is par-
ticularly detrimental to patient outcomes. It can originate
from causes related to intracranial (haematoma, swelling,
infection) and extra cranial (hypoglycaemia, hypotension,
hyperthermia, hypoxia) factors.9
The intervention of interest in this review, Hypertonic Sal-
ine (HTS), refers to osmotic solution with a sodium chloride
concentration greater than found in normal human physiol-
ogy. HTS has a variety of clinical effects, but in TBI its admin-
istration aims to prevent and/or treat the effects of secondary
brain injury.7
During hypovolaemic shock, HTS is useful due to its ability
to expand the plasma volume by drawing ﬂuids from the extra-
vascular spaces into the intravascular space.10HTS prevents,
controls and/or decreases intracranial pressure (ICP) through
this osmotic effect, drawing ﬂuids from the oedematous brain
tissue, which in turn reduce brain volume.11Apart from
improving haemodynamic status and decreasing ICP, HTS
also shows favourable vasoregulatory, immunomodulatory
and neurochemical effects.7,11,12
The Cochrane review by Bunn 2008 focused on ﬂuid resus-
citation with the objective to establish whether HTS decreases
the mortality of critically ill patients with hypovolaemia (with
and without TBI).13 It includes 14 RCTs and found insufﬁcient
data to make conclusions. As explained HTS may beneﬁt TBI
patients, however this remains inconclusive. This review exam-
ined the effect of HTS compared to SFT in TBI, irrespective of
hypovolaemia and also contains outcomes not considered by
Bunn 2008.13 It adds to existing literature and examined avail-
able data in the anticipation to make informed decisions on the
treatment of TBI.7,14 Our objective was to assess the effects of
HTS compared to SFT in the treatment and resuscitation of
patients with TBI.Methods
Criteria for considering studies for the review
RCTs of adult and paediatric patients with severe blunt TBI
(GCS < 9/15) who received HTS compared to SFT [Ringers
Lactate (RL) or Normal Saline (NS)] were included. The pri-
mary outcomes were mortality, morbidity and haemodynamic
stability. Secondary outcomes were ICP, CPP, adverse events
secondary to HTS, serum sodium levels and economical impli-
cations of both therapies.Identiﬁcation of studies for inclusion
Potentially eligible RCTs were identiﬁed by comprehensive
searches (Table 1a–c: data supplement, available online) of
the following electronic databases (May 2010): Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), MEDLINE
(from 1966), EBSCOhost (Academic Search Premier, Africa-
wide: NiPAD and Cinahl), Scopus, ScienceDirect, Proquest
Medical Library and EMBASE (from 1980). Searches were
updated in February 2011 (excluding EMBASE) and not lim-
ited by year or language of publication. Reference lists of
included RCTs were reviewed for eligible publications and ﬁrst
authors contacted to identify ongoing or unpublished RCTs.
Conference and congress proceedings: International Trauma
Conference 2009, 4th International Hokkaido Trauma Confer-
ence 2010 and 8th World Congress on Trauma, Shock, Inﬂam-
mation and Sepsis were searched (June 2010) for relevant
abstracts. The South African National Trials Registry, Clini-
calTrials.gov and WHO International Clinical Trials Registry
Platform were searched to identify relevant protocols and
ongoing RCTs in June 2010 and updated in Feb 2011.
Selecting eligible studies and data extraction
Following de-duplication, titles were reviewed for relevance.
Abstracts of the study titles deemed relevant were reviewed
for eligibility using the pre-speciﬁed eligibility criteria. Full text
reports were retrieved and study eligibility judged by two inde-
pendent reviewers. Data of included studies were captured
independently on a data extraction form. Disagreements were
resolved through discussion.
Risk of bias in included studies
The risk of bias within included studies was assessed indepen-
dently usingTheCochraneCollaborationRisk ofBias tool. This
tool judges RCTs as high, low or unclear risk of bias in the fol-
lowing domains: sequence generation, allocation concealment,
blinding of participants, personnel and outcome assessors,
incomplete data, selective reporting and other possible sources
of bias. Primary authors of included RCTs were contacted to
clarify information (Table 3: data supplement, available online).
Data analysis
RevMan 5.1 software (2011) was used to perform meta-analy-
ses. For dichotomous outcomes, RR and 95%CI were calcu-
lated and where appropriate, the Mantel–Haenszel method
of meta-analysis was used. For continuous outcomes, mean
difference (MD) and 95%CI and where appropriate the
Inverse Variance method of meta-analysis was used. Heteroge-
neity was assessed using a Chi2 test with a P value of 0.10 used
for statistical signiﬁcance and quantiﬁed using the I2 statistic.
With no signiﬁcant evidence of heterogeneity (I2 < 40%) a
ﬁxed-effects model of analysis was used, alternatively a ran-
dom-effect model was appropriate. When meta-analysis was
inappropriate, the results were interpreted and presented with-
out an overall statistic.
If present, and depending on the number of studies
included, heterogeneity was to be explored through the
190 A. Lourens, J.C. Bothafollowing subgroup analyses: age, haemodynamic stability,
concentration of HTS and setting as well as a sensitivity anal-
ysis, between the ﬁxed and random-effects models conducted.Results
Results of the search
The search identiﬁed 306 potential titles. Twenty of the identi-
ﬁed titles were selected as possibly relevant and full text articles
retrieved for eligibility assessment. Of these, fourteen were
excluded and three included (Figure 1). The three remaining
titles included a duplicate RCT, an additional abstract of
included RCTs and a protocol.15–17
Included studies
Bulger 2010,18 is one of two double-blinded RCTs (Table 2)
conducted concurrently with the same intervention but twoFigure 1 Flow diagram of study selectiodifferent patient cohorts, hypovolaemic shock and TBI. The
TBI cohort received either 7.5% HTS in 6% Dextran-70
250 ml, 7.5% HTS 250 ml and 0.9% NS 250 ml, all adminis-
tered as a one-time IV bolus in the pre-hospital setting. A total
of 1331 participants were randomised however in the HTS/
dextran and HTS groups, 14 patients and 21 patients in the
NS group did not receive treatment as intended. Three hun-
dred and ﬁfty-nine patients received HTS/dextran (373 ran-
domised), 341 received HTS (355 randomised) and 582
received NS (603 randomised). Data from the HTS/dextran
cohort were not included in the meta-analysis. The primary
outcome was six month neurologic status based on the
Extended Glasgow Outcome Score (GOSE).
Cooper 2004,15,19 a double-blinded RCT (Table 2), com-
pared 250 ml 7.5% HTS and 250 ml RL. TBI patients with a
GCS < 9 and SBP < 100 mmHg were eligible and random-
ised to receive either of the study ﬂuids in addition to standard
intravenous resuscitation. Of 229 patients, 114 received HTS
with one patient withdrawing consent, and 115 received RL
with two withdrawing consent. Primary outcomes weren. RCT, randomised controlled trial.
Table 2 Included studies.
Bulger 201018 Description
Methods Double blind, 3 groups RCT conducted in 114 North American emergency medical services agencies over a 6-month
follow-up period
Participants Patients eligible for the TBI cohort had to be 15 years of age and older, GCS Score of 8 or less, sustained blunt
mechanism of injury and ineligibility for enrolment into haemorrhagic shock cohort. The haemorrhagic shock cohort
included patients with a systolic blood pressure (SBP) of 70 mmHg or 71 mmHg to 90 mmHg with an associated heart
rate of P108 per minute (Total participants: 1331)
Intervention (1) 7.5% HTS in 6% Dextran-70 250 ml dose given as a one-time IV bolus in the pre-hospital setting (373
participants)
(2) 7.5% HTS 250 ml dose given as a one-time IV bolus in the pre-hospital setting (355 participants)
(3) Comparator: 0.9% NS 250 ml dose given as a one-time IV bolus in the pre-hospital setting (603 participants)
Outcomes Primary Outcome Measures: 6 Month Neurologic status based on the GOSE
Additional assessments of neurological outcomes: GOSE at discharge and 1 month after discharge and DRS at
discharge, 1 month after discharge and 6 months after the injury
Secondary Outcome Measures: Survival to discharge, 28 day survival, ICP, interventions required to manage
intracranial hypertension, ﬂuid and blood requirements in the ﬁrst 24 h, physiologic parameters of organ dysfunction,
28 day ARDS-free survival, Multiple Organ Dysfunction Score and Nosocomial infections
Cooper 200419 Description
Methods Double Blinded RCT conducted in Melbourne, Australia over a 6 month follow-up period
Participants TBI Patients with GCS of <9 and SBP of <100 mmHg (Total participants: 229)
Exclusion criteria: Penetrating trauma, younger than 18 years, were pregnant, had no IV access, had a serious
premorbid disease on a medical identiﬁcation bracelet, had peripheral oedema, were in close proximity to receiving
hospital (scoop and run), had absent sinus rhythm, or cardiac arrest
Intervention (1) 250 ml of 7.5% HTS (114 participants)
(2) 250 ml of RL solution (115 participants) as a rapid once oﬀ infusion in addition to standard IV resuscitation ﬂuids
Outcomes Primary outcomes – Functional neurological outcomes – survival to hospital discharge, survival at 3 and 6 months,
GOS and GOSE score at 3 and 6 months
Secondary outcomes: First ICP and CPP, Duration of elevated ICP and inadequate CPP, worst oxygenation (lowest
PaO2 / FiO2 ratio) and duration of inotropic support and mechanical ventilation. Functional independence measure
(measure physical and cognitive independence) and Rancho Los Amigos score (Measure cognitive function)
Simma 199820 Description
Methods RCT conducted in Zurich, Switzerland followed up until hospital discharge
Participants Consecutive children (younger than 16 years) with severe traumatic brain injuries (GCS < 8/15) admitted to ICU of
the children’s Hospital of Zurich (Total participant: 32)
Intervention (1) HTS (sodium 268 mmol/L, 598 mOsm/L) (15 participants)
(2) RL solution over 72 h period (17 participants)
Outcomes Primary Outcomes: (1) Correlation between ICP and Serum sodium concentration for both groups. (2) Correlation
between CPP and serum sodium concentration for both groups
Secondary Outcomes: (1) Number of interventions to keep ICP within normal limits (2) Additional changes in ﬂuid
volumes (3) Clinical outcome variables (Days in ICU, Days of mechanical ventilation, survival rate and number of
patients with predeﬁned complications)
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tal discharge, survival at three and six months, GOS and
GOSE score at three and six months.
Simma 1998,16,20 a RCT of consecutive children with
severe TBI, admitted to ICU (Table 2). Of the 32 partici-
pants, seventeen were randomised to receive RL and ﬁfteen
to receive HTS over a 72-h period. The primary outcomes
aimed to correlate, ICP and serum sodium concentration
as well as CPP and serum sodium concentration for both
groups.
Risk of bias of included studies
Allocation sequence generation was adequate in two RCTs
and unclear in the third.18–20 Cooper 2004 incorporated block
randomisation stratiﬁed by ambulance and hospital.19 Bulger
2010 used a randomly generated numeric code. Simma 1998
omitted to clarify the sequence generation, merely stated that
randomisation occurred.20Allocation concealment and blinding were adequate for two
RCTs,18,19 whereas allocation concealment was not reported
and blinding impossible in the third.20 The RCTs incorporat-
ing blinding used identical intravenous bags, and paramedics,
clinicians, patients and the study coordinator were blinded to
treatment allocation.18,19
Bulger 2010 addressed missing data for the primary out-
come six-month neurologic outcome through multiple hot
deck imputations.18 Cooper 2004 had same missing data, but
it appeared to be consistent across the two groups and modi-
ﬁed intention-to-treat analyses were conducted.19 Simma
1998 had no missing data.20
Bulger 2010 is free from selective reporting, due to the fact
that pre-speciﬁed outcomes in the study protocol were
reported.17 The study protocols of Cooper 2004 and Simma
1998 were not available.19,20 Bulger 2010 was stopped in
2009 by the Data and Safety Monitoring Board, because the
futility boundary was crossed.18 The remaining RCTs seemed
to be free from other sources of bias.19,20
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A meta-analysis was conducted for mortality at hospital dis-
charge however the comparison (3 RCTs; 1184 patients; RR
0.91, 95%CI 0.76 to 1.09) (Figure 2) presented no statistically
signiﬁcant difference. No heterogeneity (Chi2 = 0.96,
P= 0.62; I2 = 0%) was found and the ﬁxed effect model
was used. In addition, RCT by Cooper 2004 (229 patients)
reported no statistically signiﬁcant difference between mortal-
ity at three months (RR 0.87, 95%CI 0.67 to 1.14) and six
months (RR 0.72, 95%CI 0.43 to 1.21).19
For the meta-analysis of mean initial GCS no statistically
signiﬁcant difference was found (2 RCTs; 955 patients; MD
0.12, 95%CI 0.40 to 0.20; Chi2 = 0.13, P= 0.72;
I2 = 0%) between the two groups. In addition, Cooper 2004
presented a median initial GCS of 4 and interquartile range
(IQR) of 3 to 7 for both groups and concluded no statistically
signiﬁcant difference in the median and IQR for the GOSE for
each group at three months (p= 0.65) and six months
(p= 0.45).19 The study further found no statistically signiﬁ-
cant difference between the two groups for the Rancho Los
Amigos score and Functional independence score at three
and six months. Bulger 2010 presented no statistically signiﬁ-
cant mean difference for 6 months GOSE 6 4 for the HTS
and NS group for the completer (MD 2.3, 95%CI 4.9 to
9.4) and imputed analysis (MD 2.9, 95%CI 4.0 to 9.7).18
The DRS at discharge presented no statistically signiﬁcant dif-
ference (p= 0.84) between the two groups.
Simma 1998 presented no SBP data before and after the
administration of the two interventions.20 Cooper 2004 pre-
sented a pre-enrolment median SBP of 80 mmHg and IQR
of 38–90 mmHg for the HTS group (114 patients) and median
SBP of 70 mmHg and IQR of 0–85 mmHg for the control
group (115 patients).19 The median SBP and IQR upon admis-
sion were 120 mmHg and 90–140 mmHg for the HTS group
(109 patients) and 115 mmHg and 90–135 mmHg for the con-
trol group (107 patients). Bulger 2010 presented no SBP data
before administration however the mean and standard devia-
tion (SD) of SBP upon hospital admission were reported as
136.9 mmHg (mean) and 33.5 mmHg (SD) for the HTS group
(341 patients).18 The control group (582 patients) had a mean
SBP of 139.1 mmHg and SD of 33.1 mmHg. No statistically
signiﬁcant difference between the mean SBP was found (1
RCT; 923 patients; MD 2.20 mmHg, 95%CI 6.66 to 2.26).
RCTs included no data on MAP. Bulger 2010 and Simma
1998 presented no data on pulse rates.18,20 Cooper 2004 pre-
sented pre-enrolment mean pulse rate and SD of 100 BPM
(beats per minute) and 33 BPM for the HTS group (108
patients). The mean pulse rate and SD of the control group
(113 patients) were 100 BPM and 35 BPM, respectively.
Secondary outcomes of interventions
In Bulger 2010,18 the ICP mean difference as measured after
hospital admission was not statistically signiﬁcant (248
patients; MD 3.50, 95%CI 7.04 to 0.04). Cooper 2004
reported the median and IQR of ICP for the two groups after
admission to the ICU. The HTS group (37 patients) showed a
median of 10 mmHg and IQR of 6–17 mmHg, whereas the
control group (49 patients) had a median of 15 mmHg and
IQR of 8.5–22 mmHg.19 The study by Simma 1998 reportedan inverse correlation between serum sodium and mean ICP
in both the HTS group (15 patients, r= 0.29, r2 = 0.08,
p< 0.001) and the control group (17 patients, r= 0.13,
r2 = 0.02, p< 0.03).20However, there were no statistically sig-
niﬁcant differences in mean ICP and serum sodium between
the two groups.
The meta-analysis for mean difference of CCP concluded a
statistically signiﬁcant difference (2 RCTs; 1005 patients; MD
3.83 mmHg, 95%CI 1.08 to 6.57) (Figure 3) indicating a lower
CPP in the SFT group. No heterogeneity was found between
studies (Chi2 = 0.00, P= 0.96; I2 = 0%) and as a result a
ﬁxed-effect model was used. In addition, the study by Simma
1998 reported a statistically signiﬁcant correlation between
serum sodium and mean CPP in the HTS group (15 patients,
r= 0.2, r2 = 0.04, p 0.002), whereas the correlation for the
control group was not statistically signiﬁcant (17 patients,
r= 0.09, r2 = 0.008, NS).20 Overall, there were no statisti-
cally signiﬁcant differences in the correlation of serum sodium
and CPP between the two groups.
Simma 1998,20 reported no statistically signiﬁcant differ-
ence (p= 0.09, Fisher’s exact test) between the two groups
for two or more complications (Table 4: data supplement,
available online). However, there was a statistically signiﬁcant
difference in the development of Adult Respiratory Distress
Syndrome (ARDS) between the two groups (p= 0.01, Fisher’s
exact test). Bulger 2010 reported a higher rate of nosocomial
infections in the HTS group which they related to the higher
rate of bloodstream and urinary tract infection.18 The study
concluded that there was no statistically signiﬁcant difference
in the adverse events between the groups (Table 4: data supple-
ment, available online). Cooper 2004 presented no adverse
event data.19
The meta-analysis for serum sodium levels concluded a sta-
tistically signiﬁcant difference between the two groups (2
RCTs; 1125 patients; MD 8 mEq/L, 95%CI 7.47 to 8.53;
Chi2 = 0.00, P= 1.00; I2 = 0%) (Figure 4), indicating lower
serum sodium levels for the SFT group. No heterogeneity
was found between studies (Chi2 = 0.00, P= 1.00; I2 = 0%)
and as a result a ﬁxed-effect model was used. RCTs included
no data on ﬁnancial implications of both therapies. No sub-
group or sensitivity analyses were required as the heterogeneity
(I2) was 0% in all meta-analyses.Discussion
This review included three RCTs (1184 patients) conducted in
North America, Australia and Switzerland between 1992 and
2009. The administration of HTS in comparison to SFT for
patients with TBI does not reduce mortality at hospital dis-
charge (RR 0.91, 95%CI 0.76 to 1.09). Furthermore, HTS
does not appear to reduce morbidity in terms of improving
neurological status after TBI. There were no clear difference
between HTS and SFT in terms of improving haemodynamical
stability and insufﬁcient data to indicate if ICP were consider-
ably different. However, TBI patients receiving HTS had a
higher CPP (MD 3.83 mmHg, 95%CI 1.08 to 6.57) and higher
serum sodium levels (MD 8 mEq/L, 95%CI 7.47 to 8.53) than
patients receiving SFT. Evidence suggests that low CPP is
potentially detrimental to TBI patients however the most
favourable CPP is less apparent. Cerebral auto-regulation
may be disturbed by TBI and in order to avoid secondary
Figure 2 Forest plot – Mortality (at hospital discharge).
Figure 3 Forest plot – CPP, cerebral perfusion pressure (mmHg).
Figure 4 Forest plot – serum sodium level – admission (mEqL).
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recent study conducted in 2012 concluded that hypernatremia
in TBI patients admitted to Neurosurgical Intensive Care
Units increases the odds of death.23
All RCTs in the review reported mortality or survival rate.
The reporting of morbidity varied due to the use of different
measurement tools amongst trials, and incomplete data on
the restoration of haemodynamical stability. Data on second-
ary outcomes were more complete. Two RCTs presented data
on adverse events,18,20 both indicate no difference between
treatment groups. No economic data were reported. Included
RCTs did not assess different concentrations, volumes or time
of HTS administration and therefore limiting the overall appli-
cability of the ﬁndings. Although three RCTs were included in
the review the majority of the data (97%) originated from the
two high to moderate quality studies.18,19
In order to avoid publication bias, a comprehensive search
of various databases, trial registries and conference proceed-
ings was conducted, without language or publication time
restrictions. Authors of included studies were contacted to
identify ongoing or unpublished studies. Study selection and
data extraction were done independently to avoid selection
bias. The number of included studies was insufﬁcient to assess
publication bias with a funnel plot.
HTS has long been proposed to be beneﬁcial in the manage-
ment of TBI secondary to a variety of mechanisms of
effect.12,14 The basis for this data was from small observational
studies or case reports.14 The review by Bunn 2008 included
two of the three RCTs included in this review.13,19,20 The
objective was to establish whether HTS decreases mortalityin patients with hypovolaemia with and without head injuries.
The review included trauma, surgery and burns patients.
Although, the review details the possible beneﬁts of HTS in
TBI, the authors only conducted a meta-analysis on trauma
with hypovolaemia, which showed no statistically signiﬁcant
difference in mortality. The analysis of poor outcomes in terms
of GCS incorporated one RCT demonstrating no difference
between the interventions.19 Bunn 2008 mentioned the poten-
tial beneﬁt of HTS in TBI but pointed to a lack of sufﬁcient
data to examine this beneﬁt. The review included Cooper
2004 and Simma 1998,13,19,20 however stated in discussion that
only one small trial examined the effect of HTS amongst TBI
patients.20 The reason for not including Cooper 2004 to the
TBI data was not provided.19 Similar to Bunn 2008, the cur-
rent review identiﬁes a deﬁciency of sound evidence to support
the use of HTS compared to SFT and indicates a need for fur-
ther research.
The lack of evidence to indicate that HTS compared to SFT
improve mortality and morbidity in TBI patient suggest that in
low resource setting where HTS is not readily available or too
costly, using SFT will not be signiﬁcantly detrimental.Conclusion
Existing research does not indicate that HTS contributes to a
reduction in mortality or improve neurological outcomes fol-
lowing TBI. Nevertheless, the use of different concentrations,
volumes and bolus versus continuous infusion of HTS as well
as the timing of administration may present some clinical
194 A. Lourens, J.C. Bothasigniﬁcance. In addition, HTS may have some clinical impor-
tance in speciﬁc injury proﬁles.
These uncertainties make formulating irrefutable recom-
mendations related to the use of HTS in TBI problematic
and identify the areas lacking high quality data in need of fur-
ther research. Research aimed to clarify these gaps in the
knowledge may also be difﬁcult to justify, as considerable
patient cohorts may be required to recognise potentially small
treatment effects.
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